Abstract
Objective: This review aims to illuminate the unprecedented growth and versatile therapeutic landscape of monoclonal antibody (mAb) products, highlighting their significant impact on diverse medical fields such as oncology, septicemia treatment, infection management, and substance abuse disorder interventions. This review outlines the challenges associated with the development, manufacturing, and regulatory approval of monoclonal antibodies, emphasizing the need for diligent attention to overcome these complexities. The review comprehensively examines the historical evolution and therapeutic applications of monoclonal antibodies, emphasizing their potent and versatile characteristics that have enabled successful interventions in challenging regulatory approvals. It delves into the critical considerations in manufacturing, regulatory navigation, and the strategic integration of expedited approval pathways, providing a holistic understanding of the intricate terrain of innovation, clinical translation, and impactful patient care in the realm of monoclonal antibody products. Monoclonal antibodies have significantly advanced medical treatment in various domains, revolutionizing cancer therapy, offering new avenues for septicemia management, augmenting the arsenal against infections, and opening novel pathways for addressing substance abuse disorders. Their development and regulatory approval are associated with challenges of scientific innovation, manufacturing, and regulatory compliance. Despite the challenges, monoclonal antibodies have demonstrated remarkable potential in addressing complex medical conditions. The review serves as a compass, guiding researchers, clinicians, and regulatory authorities through the intricate terrain of monoclonal antibody innovation and clinical translation. It emphasizes the need for diligent attention to overcome the complexities associated with their development and regulatory approval while highlighting their significant impact on advancing patient care.
Publisher
Innovare Academic Sciences Pvt Ltd
Reference50 articles.
1. WHO Guideline for the safe production and quality control of monoclonal antibodies for use in humans. Available from: https://cdn.who.int/media/docs/default-source/BioLogicals/mabs-manufacture-guideline-draft-for-1st-public-comment.pdf. [Last accessed on 19 Aug 2023]
2. Weinberg WC, Frazier Jessen MR, Wu WJ, Weir A, Hartsough M, Keegan P. Development and regulation of monoclonal antibody products: challenges and opportunities. Cancer Metastasis Rev. 2005 Dec;24(4):569-84. doi: 10.1007/s10555-005-6196-y, PMID 16408162.
3. Lynch CM, Grewal IS. Preclinical safety evaluation of monoclonal antibodies. Handb Exp Pharmacol. 2008;(181):19-44. doi: 10.1007/978-3-540-73259-4_2, PMID 18071940.
4. Quinteros DA, Bermudez JM, Ravetti S, Cid A, Allemandi DA, Palma SD. Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery. Nanostruct Drug Deliv. 2017 Jan 1;807-33. doi: 10.1016/B978-0-323-46143-6.00025-7
5. Lyu X, Zhao Q, Hui J, Wang T, Lin M, Wang K. The global landscape of approved antibody therapies. Antib Ther. 2022 Oct 1;5(4):233-57. doi: 10.1093/abt/tbac021, PMID 36213257.